This finding was compatible with that of Yagi et al., who noted a better glucose-lowering effect in patients with type 2 diabetes receiving SGLT2 inhibitor treatment who had a high baseline HbA1c level (29). Here, SLC5A2 is linked to type 2 diabetes mellitus.